Pathstone Holdings’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Pathstone Holdings’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-49,158	Closed	-$494K	–	2367
2023 Q4	$494K	Buy	+49,158	New	+$223K	﹤0.01%	1514

Pathstone Holdings's GRCL Position: Q1 2024 in Review

Pathstone Holdings sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 49,158 shares — an estimated $494K sold.

Pathstone Holdings first reported a position in GRCL in Q4 2023 and held it in 1 quarter. The position peaked at $494K in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Pathstone Holdings reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Pathstone Holdings sold 49,158 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $494K.
Pathstone Holdings first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2023 and held it in 1 quarter.
Pathstone Holdings's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $494K in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Pathstone Holdings's 13F filing for Q1 2024, filed 13 May 2024.